Quick Answer
Cullinan Therapeutics, Inc. reported Operating Income of -$241.65 million for fiscal year 2025.
Cullinan Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$241.65M | -22.7% |
| 2024 | -$196.92M | -3.1% |
| 2023 | -$191.09M | -232.1% |
| 2022 | $144.65M | +312.9% |
| 2021 | -$67.95M | -12.6% |
| 2020 | -$60.34M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$55.59M | -13.8% | +26.7% |
| June 30, 2025 | -$75.80M | -51.5% | -37.8% |
| March 31, 2025 | -$55.00M | -27.9% | -12.6% |
| September 30, 2024 | -$48.85M | -8.0% | +2.3% |
| June 30, 2024 | -$50.03M | -33.0% | -16.4% |
| March 31, 2024 | -$42.99M | +31.5% | +5.0% |
| September 30, 2023 | -$45.24M | -52.0% | -20.3% |
| June 30, 2023 | -$37.60M | -115.7% | +40.1% |
- Cullinan Therapeutics, Inc. showed a decrease of -22.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Cullinan Therapeutics, Inc.’s operating income has declined by 300.5% (from -$60.34 million to -$241.65 million).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: